Rangel-Moreno Karla, Gamboa-Loira Brenda, López-Carrillo Lizbeth, Cebrián Mariano E
Instituto Nacional de Salud Pública, Av. Universidad 655, Col. Santa María Ahuacatitlán, C.P. 62100, Cuernavaca, Morelos, Mexico.
Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados Del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Ciudad de México, C.P. 07360, Mexico.
Environ Res. 2022 Jul;210:112948. doi: 10.1016/j.envres.2022.112948. Epub 2022 Feb 19.
Experimental studies have shown the diabetogenic potential of inorganic arsenic (iAs); however, the epidemiological evidence is still inconclusive. This could be explained by differences in exposure, metabolism efficiency, nutritional and genetic factors.
To evaluate the association between type 2 diabetes mellitus (T2DM) prevalence with arsenic exposure and metabolism, considering one-carbon metabolism nutrient intake and arsenite methyltransferase (AS3MT) polymorphisms.
From healthy controls of a case control study for female breast cancer in northern Mexico, 227 self-reported diabetic women were age-matched with 454 non-diabetics. Participants were interviewed about dietary, sociodemographic and clinical characteristics. Urinary iAs metabolites were determined by HPLC-ICP-MS, methylation efficiency parameters were calculated, and AS3MT c.860 T > C and c.529-56G > C genotypes were determined. Unconditional logistic regression models were used to evaluate associations.
Total arsenic in urine (TAs) ranged from 0.73 to 248.12 μg/L with a median of 10.48 μg/L. In unadjusted analysis, TAs (μg/g) was significantly higher in cases than controls, but not when expressed as TAs (μg/L). Cases had significantly lower urinary monomethylarsonic acid percentage (%MMA), first methylation ratio (FMR), creatinine, and choline and selenium intakes. In multi-adjusted models and in women without HTA history T2DM showed significant positive associations with %iAs and FMR, respectively, and a significant negative association with %DMA. In participants with HTA history there was a marginal positive association (p = 0.08) between T2DM and TAs concentrations (μg/g) without other significant associations.
Our results support an association between T2DM prevalence and iAs metabolism but not with urinary arsenic levels. However, elucidation of the interplay among iAs metabolism, T2DM and HTA merit further studies.
实验研究已表明无机砷(iAs)具有致糖尿病的潜在可能性;然而,流行病学证据仍不确凿。这可能是由于暴露、代谢效率、营养和遗传因素的差异所致。
考虑一碳代谢营养素摄入和亚砷酸盐甲基转移酶(AS3MT)基因多态性,评估2型糖尿病(T2DM)患病率与砷暴露及代谢之间的关联。
从墨西哥北部一项女性乳腺癌病例对照研究的健康对照中,选取227名自我报告患有糖尿病的女性与454名非糖尿病女性进行年龄匹配。对参与者进行饮食、社会人口学和临床特征方面的访谈。通过高效液相色谱 - 电感耦合等离子体质谱法测定尿中iAs代谢产物,计算甲基化效率参数,并确定AS3MT基因c.860 T>C和c.529 - 56G>C基因型。使用无条件逻辑回归模型评估关联。
尿中总砷(TAs)范围为0.73至248.12μg/L,中位数为10.48μg/L。在未调整分析中,病例组尿中TAs(μg/g)显著高于对照组,但以TAs(μg/L)表示时则不然。病例组的尿一甲基胂酸百分比(%MMA)、首次甲基化率(FMR)、肌酐以及胆碱和硒摄入量显著较低。在多因素调整模型中以及在无高血压病史的女性中,T2DM分别与%iAs和FMR呈显著正相关,与%DMA呈显著负相关。在有高血压病史的参与者中,T2DM与TAs浓度(μg/g)之间存在边缘正相关(p = 0.08),无其他显著关联。
我们的结果支持T2DM患病率与iAs代谢之间存在关联,但与尿砷水平无关。然而,阐明iAs代谢、T2DM和高血压之间的相互作用值得进一步研究。